Skip to main content
SpringerLink
Log in

Diagnosis and Treatment of Hallucinations and Delusions in Parkinson’s Disease

  • Chapter
Mental and Behavioral Dysfunction in Movement Disorders

  • 211 Accesses

Abstract

Hallucinations and delusions in Parkinson’s disease (PD) have attracted attention because they are common, have important clinical consequences both for patients, their families, and the health care system, and they are treatable. According to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM IV) (1), a delusion is a false belief based on incorrect inference about external reality that is firmly sustained despite what almost everyone else believes. Hallucination is a sensory perception that has the compelling sense of reality of a true perception, but that occurs without external stimulation of the relevant sensory organ. The person may or may not have insight in that he or she is having a hallucination. Psychotic symptoms such as hallucinations and delusions are the cardinal features of psychiatric disorders such as schizophrenia, schizo-affective disorder, delusional disorder, and brief psychotic disorder. Psychotic symptoms may also occur during the course of delirium or dementias and may be due to a range of other general medical and neurological conditions, including PD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th ed., American Psychiatric Association, Washington, DC.

    Google Scholar 

  2. Cummings, J.L. (1991) Behavioral complications of drug treatment of Parkinson’s disease. J. Am. Geriatr. Soc. 39, 718–716.

    Google Scholar 

  3. Gelb, D.J., Oliver, E., and Gilman, S. (1999) Diagnostic criteria for Parkinson’s disease. Arch. Neurol. 56, 33–39.

    Article  PubMed  CAS  Google Scholar 

  4. Litvan, I., MacIntyre, A., Goetz, C.G., et al. (1998) Accuracy of the clinical diagnoses of Lewy body disease, Parkinson’s disease, and dementia with Lewy bodies. Arch. Neurol. 55, 969–978.

    Article  PubMed  CAS  Google Scholar 

  5. Jellinger, K. (1999) Neuropathological correlates of mental dysfunction in Parkinson’s disease: an update, in Mental Dysfunction in Parkinson’s Disease (Wolters, E., Scheltens, P., Berendse, H.W., eds.), Academic Pharmaceutical Productions, Utrecht, The Netherlands, pp. 82–105.

    Google Scholar 

  6. Aarsland, D., Ballard, C., Larsen, J.P., and McKeith, I.G. (2001) A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementia. Int. J. Geriatr. Psychiatry 16, 528–536.

    Article  PubMed  CAS  Google Scholar 

  7. Aarsland, D., Litvan, I., and Larsen, J.P. (2001) Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci. 13, 42–49.

    Article  PubMed  CAS  Google Scholar 

  8. Aarsland, D., Cummings, J.L., and Larsen, J.P. (2001) Neuropsychiatric differences between Parkinson’s disease with dementia and Alzheimer’s disease. J. Int. Geriatr. Psychiatry 16, 184–191.

    Article  CAS  Google Scholar 

  9. Fenelon, G., Mahieux, F., and Huon, R. (2000) Hallucinations in Parkinson’s disease. Prevalence, phenomenology and risk factors. Brain 123, 733–745.

    Article  PubMed  Google Scholar 

  10. Sanchez-Ramos, J.R., Ortoll, R., and Paulson, G.W. (1996) Visual hallucinations associated with Parkinson’s disease. Arch. Neurol. 53, 1265–1268.

    Article  PubMed  CAS  Google Scholar 

  11. Naimark, D., Jackson, E., Rockwell, E., et al. (1996) Psychotic symptoms in Parkinson’s disease patients with dementia. J. Am. Geriatr. Soc. 44, 296–299.

    PubMed  CAS  Google Scholar 

  12. Graham, J.M., Grunewald, R.A., and Sagar, H.J. (1997) Hallucinations in idiopathic Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 63, 434–440.

    Article  PubMed  CAS  Google Scholar 

  13. Inzelberg, R., Kipervasser, S., and Korczyn, A.D. (1998) Auditory hallucinations in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 64, 533–535.

    Article  PubMed  CAS  Google Scholar 

  14. Aarsland, D., Larsen, J.P., Cummings, J.L., and Laake, K. (1999) Prevalence and clinical correlates of psychosis in Parkinson’s disease. Arch. Neurol. 56, 595–601.

    Article  PubMed  CAS  Google Scholar 

  15. Holroyd, D., Currie, L., and Wooten, G.F. (2001) Prospective study of hallucinations and delusions in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 70, 734–738.

    Article  PubMed  CAS  Google Scholar 

  16. Barnes, J. and David, A.S. Visual hallucinations in Parkinson’s disease: a review and phenomenological survey. J. Neurol. Neurosurg. Psychiatry 70, 727–733.

    Google Scholar 

  17. Aarsland, D., Larsen, J.P., Lim, N.G., et al. (1999) Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 67, 492–496.

    Article  PubMed  CAS  Google Scholar 

  18. Sweet, R.D., McDowell, F.H., Feigenson, J.S., Loranger, A.W., and Goodel, H. (1976) Mental symptoms in Parkinson’s disease during chronic treatment with levodopa. Neurology 26, 305–310.

    Article  PubMed  CAS  Google Scholar 

  19. Bell, K., Dooneief, G., Marder, K., et al. (1991) Non-drug-induced psychosis in Parkinson’s disease. Neurology 41 (Suppl. 1), 191.

    Google Scholar 

  20. Goetz, C.G., Leurgans, S., Pappert, E.J., Raman, R., and Stemer, A.B. (2001) Prospective longitudinal assessment of hallucinations in Parkinson’s disease. Neurology 57, 2078–2082.

    Article  PubMed  CAS  Google Scholar 

  21. Peyser, C.E., Naimark, D., Zuniga, R., and Jeste, D. (1998) Psychoses in Parkinson’s disease. Semin. Clin. Neuropsychiatry 3, 41–50.

    PubMed  Google Scholar 

  22. Small, G.W. and Salzman, C. (1998) Treatment of depression with new and atypical antidepressants, in Clinical Geriatric Psychopharmacology, 3rd ed. (Salzman, C., ed.), Williams & Wilkins, Baltimore, pp. 245–261.

    Google Scholar 

  23. Cummings, J.L. (1992) Depression and Parkinson’s disease: a review. Am. J. Psychiatry 149, 443–454.

    PubMed  CAS  Google Scholar 

  24. Tandberg, E., Larsen, J.P., Aarsland, D., Laake, K., and Cummings, J.L. (1997) Risk factors for depression in Parkinson’s disease. Arch. Neurol. 54, 625–630.

    Article  PubMed  CAS  Google Scholar 

  25. Comella, C.L., Tanner, C.A., and Ristanovic, R.K. (1993) Polysomnographic sleep measures in non-demented Parkinson’s disease patients with treatmentinduced hallucinations. Ann. Neurol. 34, 710–714.

    Article  PubMed  CAS  Google Scholar 

  26. Tandberg, E., Larsen, J.P., and Karlsen, K. (1999) Excessive daytime sleepiniess and sleep benefit in Parkinson’s disease: a community-based study. Mov. Disord. 14, 922–927.

    Article  PubMed  CAS  Google Scholar 

  27. Pappert, E.J., Goetz, C.G., Niederman, F.G., et al. (1999) Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson’s disease. Mov. Disord. 14, 117–121.

    Article  PubMed  CAS  Google Scholar 

  28. Goetz, C.G. and Stebbins, G.T. (1995) Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology 45, 669–676.

    Article  PubMed  CAS  Google Scholar 

  29. Aarsland, D., Larsen, J.P., Karlsen, K., Lim, N.G., and Tandberg, E. (1999) Mental symptoms in Parkinson’s disease are important contributors to caregiver distress. Int. J. Geriatr. Psychiatry 14, 866–874.

    Article  PubMed  CAS  Google Scholar 

  30. Thommessen, B., Aarsland, D., Braekhus, A., Oksengaard, A.R., Engedal, K., and Laake, K. (2002) The psychosocial burden on spouses of the elderly with stroke, dementia and Parkinson’s disease. Int. J. Geriatr. Psychiatry 17, 78–84.

    Article  PubMed  Google Scholar 

  31. Larsen, J.P. and the Norwegian Study Group of Parkinson’s Disease in the Elderly (1991) Parkinson’s disease as community health problem: study in Norwegian nursing home. BMJ 303, 741–743.

    Article  PubMed  CAS  Google Scholar 

  32. Aarsland, D., Larsen, J.P., Tandberg, E., and Laake, K. (2000) Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J. Am. Geriatr. Soc. 48, 938–942.

    PubMed  CAS  Google Scholar 

  33. Hurtig, H.I., Trojanowski, J.Q., Galvin, J., et al. (2000) Alpha-synuclein cortical lewy bodies correlate with dementia in Parkinson’s disease. Neurology 54, 1916–1921.

    Article  PubMed  CAS  Google Scholar 

  34. Friedberg, G., Zoldan, J., Weizman, A., and Melamed, E. (1998) Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson’s disease. Clin. Neuropharmacol. 21, 280–284.

    PubMed  CAS  Google Scholar 

  35. Cummings, J.L., Mega, M., Gray, K., et al. (1994) The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44, 2308–2314.

    Article  PubMed  CAS  Google Scholar 

  36. Goetz, C.G., Vogel, C., Tanner, C.M., and Stebbins, G.T. (1998) Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 51, 811–814.

    Article  PubMed  CAS  Google Scholar 

  37. McKeith, I.G., Galasko, D., Kosaka, K., et al. (1996) Consensus guidelines for the clinical diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47, 1113–1124.

    Article  PubMed  CAS  Google Scholar 

  38. Aarsland, D., Salmon, D., Galasko, D., and Larsen, J.P. (2001) Cogntion in dementia with Lewy-bodies and Parkinson’s disease. Mov. Disord. 16(Suppl. 1), A524.

    Google Scholar 

  39. Aarsland, D., Ballard, C., McKeith, I., Perry, R.H., and Larsen, J.P. Comparison of extrapyramidal signs in Dementia with Lewy bodies and Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci., in press.

    Google Scholar 

  40. Pillon, B., Dubois, B., Lhermitte, F., et al. (1986) Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson’s disease, and Alzheimer’s disease. Neurology 36, 1179–1185.

    Article  PubMed  CAS  Google Scholar 

  41. Heyman, A., Fillenbaum, G.G., Gearing, M., et al. (1999) Comparison of Lewy body variant of Alzheimer’s disease with pure Alzheimer’s disease. Neurology 52, 1839–1844.

    Article  PubMed  CAS  Google Scholar 

  42. Byerly, M.J., Weber, M.T., Brooks, D.L., Snow, L.R., Worley, L.A., and Lescouflair, E. (2001) Antipsychotic medications and the elderly. Effects on cognition and implications for use. Drugs Aging 18, 45–61.

    Article  PubMed  CAS  Google Scholar 

  43. Mjønes, H. (1949) Paralysis agitans. A clinical and genetic study. Acta. Psychiatr. Scand. 54(Suppl. 54).

    Google Scholar 

  44. Goetz, C.G., Pappert, E.J., Blasucci, L.M., et al. (1998) Intravenous levodopa in hallucinating Parkinson’s disease patients: high-dose challenge does not precipitate hallucinations. Neurology 50, 515–517.

    Article  PubMed  CAS  Google Scholar 

  45. Moskowitz, C., Moses, H., and Klawans, H.L. (1978) Levodopa-induced psychosis: a kindling phenomenon. Am. J. Psychiatry 135, 669–674.

    Google Scholar 

  46. Perry, E., Wlaker, M., Grace, J., and Perry, R. (1999) Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 22, 273–280.

    Article  PubMed  CAS  Google Scholar 

  47. Zoldan, Z., Friedberg, G., Livneh, M., and Melamed, M. (1995) Psychosis in advanced Parkinson’s disease: treatment with ondansetron, a 5HT3 receptor antagonist. Neurology 45, 1305–1308.

    Article  PubMed  CAS  Google Scholar 

  48. Goetz, C.G., Tanner, C.M., and Klawans, H.L. (1982) Pharmacology of hallucinations induced by long-term drug therapy. Am. J. Psychiatry 139, 494–497.

    PubMed  CAS  Google Scholar 

  49. Fischer, P., Danielczyk, W., Simanyi, M., and Streifler, M.B. (1990) Dopaminergic psychosis in advanced Parkinson’s disease. Adv. Neurol. 53, 391–397.

    PubMed  CAS  Google Scholar 

  50. Friedman, J.H. and Factor, S.A. (2000) Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov. Disord. 15, 201–211.

    Article  PubMed  CAS  Google Scholar 

  51. Dewey, R.B. and O’Suillebeabhain, P.E. (2000) Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson’s disease. Neurology 55, 1753–1754.

    Article  PubMed  Google Scholar 

  52. Meltzer, H.Y. (2000) Antipsychotic and anticholinergic drugs, in New Oxford Textbook of Psychiatry (Gelder, M.G., Lopez-Ibor, J. Jr., and Andreassen, N.C., eds.), Oxford University Press, Oxford, pp. 1314–1326.

    Google Scholar 

  53. Auzu, P., Øzsancak, C., Hannequin, D., and Moore, N. (1996) Clozapine for the treatment of psychosis in Parkinson’s disease: a review. Acta Neurol. Scand. 94, 329–336.

    Article  Google Scholar 

  54. The Parkinson Study Group. (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N. Engl. J. Med. 340, 757–763.

    Article  Google Scholar 

  55. The French Clozapine Parkinson Study Group. (1999) Clozapine in drug-induced psychosis in Parkinson’s disease. Lancet 353, 2041–2042.

    Article  Google Scholar 

  56. Roldan-Gimenez, S., Mateo, D., Navarro, E., and Gines, M.M. (2001) Efficacy and safety of clozapine and olanzapine: an open-label study comparing two groups of Parkinson’s disease patients with dopaminergic-induced psychosis. Parkinsonism Relat. Disord. 7, 121–127.

    Article  Google Scholar 

  57. Aarsland, D., Larsen, J.P., and Lim, N.G. (1999) Olanzapin tor psychosis in patients with Parkinson’s aisease witn and without dementia. J. Neuropsychiatry Clin. Neurosci. 11, 393–394.

    Google Scholar 

  58. Targum, S.D. and Abbott, J.L. (2000) Efficacy of quetiapine in Parkinson’s patients with psychosis. J. Clin. Psychopharmacol. 20, 54–60.

    Article  PubMed  CAS  Google Scholar 

  59. Fernandez, H.H., Lannon, M.C., Friedman, J.H., and Abbott, B.P. (2000) Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson’s disease. Mov. Disord. 15, 579–581.

    Article  PubMed  CAS  Google Scholar 

  60. Mohr, E., Mendis, T., Hildebrand, K., and De Deyn, P.P. (2000) Risperdione in the treatment of dopamine-induced psychosis in Parkinson’s disease: an open pilot trial. Mov. Disord. 15, 1230–1237.

    Article  PubMed  CAS  Google Scholar 

  61. Fernandez, H. (2000) Quetiapine for 1-dopa-induced psychosis in PD. Neurology 55, 899.

    Article  PubMed  CAS  Google Scholar 

  62. Manson, A.J., Schrag, A., and Lees, A. (2000) Low-dose olanzapine for levodopa induced dyskinesias. Neurology 55, 795–799.

    Article  PubMed  CAS  Google Scholar 

  63. Goetz, C.G., Blasucci, L.M., Leurgans, S., and Pappert, E.J. (2000) Olanzapine and clozapine. Comparative effects on motor function in hallucinating PD patients. Neurology 55, 789–794.

    Article  PubMed  CAS  Google Scholar 

  64. Ellis, T., Cudkowicz, M.E., Sexton, P.M., and Growdon, J.H. (2000) Clozapine and risperidone treatment of psychosis in Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci. 12, 364–369.

    Article  PubMed  CAS  Google Scholar 

  65. Richard, I.H. and Nutt, J. (2000) Worsening of motor function in Parkinson’s disease. A “typical” response to “atypical” antipsychotic medications. Neurology 55, 748–749.

    Article  PubMed  CAS  Google Scholar 

  66. Kapur, S., Zipursky, R.B., and Remington, G. (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry 156, 286–293.

    PubMed  CAS  Google Scholar 

  67. Wolters, E.C., Jansen, E.N.H., Tuynman-Qua, H.G., and Bergamns, P.L.M. (1996) Olanzapine in the treatment of dopaminom imetic psychosis with Parkinson’s disease. Neurology 47, 1085–1087.

    Article  PubMed  CAS  Google Scholar 

  68. Green, B. (1999) Focus on quetiapine. Curr. Med. Res. Opin. 15, 145–151.

    Article  PubMed  CAS  Google Scholar 

  69. Factor, S.A., Molho, E.S., and Brown, D. (1995) Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci. 7, 304–307.

    PubMed  CAS  Google Scholar 

  70. Andersen, K., Balldin, J., Gottfries, C.G., et al. (1987) A double-blind study of electroconvulsive therapy in Parkinson’s disease with “on-off” phenomena. Acta Neurol. Scand. 76, 191–199.

    Article  PubMed  CAS  Google Scholar 

  71. Aarsland, D., Larsen, J.P., Waage, Ø., and Langeveld, H. (1997) Maintenance ECT in Parkinson’s disease. Convuls. Ther. 13, 274–277.

    PubMed  CAS  Google Scholar 

  72. Barkai, A., Durkin, M., and Nelson, D. (1990) Locapized alterations of dopamine receptor binding in rat brain by repeated electronvulsive shock: an autoradiographic study. Brain Res. 529, 208–213.

    Article  PubMed  CAS  Google Scholar 

  73. Abrams, R. (1992) Electroconvulsive Therapy, 2nd ed. Oxford University Press, New York.

    Google Scholar 

  74. Eichhirn, T., Brunt, E., and Oertel, W.H. (1996) Ondansetron treatment of 1-dopa-induced psychosis. Neurology 47, 1608–1609.

    Article  Google Scholar 

  75. Ikeguchi, K. and Kuroda, A. (1995) Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur. Arch. Psychiatry Clin. Neurosci. 244, 320–324.

    Article  PubMed  CAS  Google Scholar 

  76. Perry, E., Irving, D., Kerwin, J.M., et al. (1993) Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson’s and distinction from Alzheimer disease. Alzheimer Dis. Assoc. Disord. 7, 69–79.

    Article  PubMed  CAS  Google Scholar 

  77. Kuhl, D.E., Minoshima, S., Fessler, J.A., et al. (1996) In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease. Ann. Neurol. 40, 399–410.

    Article  PubMed  CAS  Google Scholar 

  78. Perry, E.K., Kerwin, J., Perry, R.H., Irving, D., Blessed, G., and Fairbairn, A. (1990) Cerebral cholinergic activity is related to the incidence of visual hallucinations in senile dementia of Lewy body type. Dementia 1, 2–4.

    Google Scholar 

  79. Hutchinson, M. and Fazzini, E. (1996) Cholinesterase inhibition in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 61, 324–326.

    Article  PubMed  CAS  Google Scholar 

  80. McKeith, I., Del Ser, T., Spano, P.F., et al. (2000) Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind placebo-controlled international study. Lancet 356, 2031–2036.

    Article  PubMed  CAS  Google Scholar 

  81. Kaufer, D., Cummings, J.L., and Christine, D. (1996) Effect of tacrine on behavioral symptoms in Alzheimer’s disease: an open-label study. J. Geriatr. Psychiatry Neurol. 9, 1–6.

    PubMed  CAS  Google Scholar 

  82. Aarsland, D., Laake, K., Larsen, J.P., and Janvin, C. (2002) Donepezil treatment in Parkinson’s disease with dementia: a doubleblind, placebo-controlled crossover study. Neuro. Nursing Psych. 72, 708–712.

    Article  CAS  Google Scholar 

  83. Okereke, C.S., Kumar, D., Cullen, E.I., Pratt, R.D., and Hahne, W.F. (2001) Pharmacokinetics and safety of concurrent donepezil HCl and levodopa/carbidopa administration in subjects with Parkinson’s disease. Neurology 56(Suppl. 3), A457.

    Google Scholar 

Download references

Authors
  1. Dag Aarsland MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan Petter Larsen MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Université du Québec à Montréal, Montréal, Canada

    Marc-André Bédard MSc, PhD

  2. Hôpital de la Salpêtrière, Paris, France

    Yves Agid MD, PhD

  3. Université de Montréal, Montréal, Canada

    Sylvain Chouinard MD  & Paul Lespérance MD, MSc  & 

  4. Columbia University, New York, NY, USA

    Stanley Fahn MD

  5. Tel-Aviv University Medical School, Tel-Aviv, Israel

    Amos D. Korczyn MD, MSc

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Aarsland, D., Larsen, J.P. (2003). Diagnosis and Treatment of Hallucinations and Delusions in Parkinson’s Disease. In: Bédard, MA., Agid, Y., Chouinard, S., Fahn, S., Korczyn, A.D., Lespérance, P. (eds) Mental and Behavioral Dysfunction in Movement Disorders. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-326-2_28

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-326-2_28

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-372-5

  • Online ISBN: 978-1-59259-326-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation